IN2014CN04055A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04055A IN2014CN04055A IN4055CHN2014A IN2014CN04055A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A IN 4055CHN2014 A IN4055CHN2014 A IN 4055CHN2014A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A
- Authority
- IN
- India
- Prior art keywords
- proportion
- composition
- increased
- disease
- treat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241001657523 Coriobacteriaceae Species 0.000 abstract 1
- 241001608234 Faecalibacterium Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229920001100 Polydextrose Polymers 0.000 abstract 1
- 241001430183 Veillonellaceae Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 244000005709 gut microbiome Species 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940035035 polydextrose Drugs 0.000 abstract 1
- 235000013856 polydextrose Nutrition 0.000 abstract 1
- 239000001259 polydextrose Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161555800P | 2011-11-04 | 2011-11-04 | |
PCT/US2012/063008 WO2013067146A1 (en) | 2011-11-04 | 2012-11-01 | Methods and compositions for modulating gastrointestinal bacteria to promote health |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04055A true IN2014CN04055A (ru) | 2015-10-23 |
Family
ID=48192757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4055CHN2014 IN2014CN04055A (ru) | 2011-11-04 | 2012-11-01 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20150209383A1 (ru) |
EP (1) | EP2773357A4 (ru) |
JP (1) | JP2014532710A (ru) |
KR (1) | KR20140093252A (ru) |
CN (1) | CN104159588A (ru) |
AU (1) | AU2012332491A1 (ru) |
BR (1) | BR112014010660A2 (ru) |
CA (1) | CA2854398A1 (ru) |
IN (1) | IN2014CN04055A (ru) |
MX (1) | MX2014005433A (ru) |
WO (1) | WO2013067146A1 (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201312713D0 (en) * | 2013-03-22 | 2013-08-28 | Weaver Connie M | Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption |
GB2551642B (en) | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
EP3283087A4 (en) * | 2015-04-14 | 2019-03-13 | Ubiome Inc. | METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM |
WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
GB201519088D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | The use of bacteria formulations |
WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
CN106994136A (zh) * | 2016-01-26 | 2017-08-01 | 富士胶片株式会社 | 肠内细菌数量抑制剂、食品、及药品 |
WO2017159647A1 (ja) * | 2016-03-14 | 2017-09-21 | 物産フードサイエンス株式会社 | フィーカリバクテリウム属細菌増殖剤 |
US10799540B2 (en) * | 2016-09-06 | 2020-10-13 | Bgi Shenzhen | Faecalibacterium longum and application thereof |
CN111246870B (zh) | 2017-06-02 | 2022-08-12 | 古德盖特公司 | 用于治疗生态失调的葡萄皮 |
WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
EP3466417A1 (en) * | 2017-10-04 | 2019-04-10 | Sorbonne Université | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity |
EP3723775A4 (en) | 2017-12-15 | 2022-04-13 | Solarea Bio, Inc. | MICROBIAL COMPOSITIONS AND METHODS OF TREATMENT OF TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME |
CN109998112B (zh) * | 2017-12-22 | 2024-05-14 | 奥地利商艾尔柏有限公司 | 红蝽杆菌纲促进肠道健康的用途 |
WO2019158546A1 (en) * | 2018-02-14 | 2019-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polydextrose for the treatment of inflammatory diseases |
WO2019216815A1 (en) * | 2018-05-09 | 2019-11-14 | Carbiotix Ab | Method for measuring and improving gut health |
JP7126004B2 (ja) | 2018-05-31 | 2022-08-25 | ビージーアイ シェンチェン | 組成物及びその使用 |
CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
ES2763874B2 (es) * | 2018-11-30 | 2020-10-13 | Consejo Superior Investigacion | Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades |
WO2021071864A1 (en) * | 2019-10-07 | 2021-04-15 | Siolta Therapeutics, Inc. | Therapeutic pharmaceutical compositions |
KR102174095B1 (ko) * | 2019-12-11 | 2020-11-05 | 주식회사 에이치이엠 | 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물 |
CN117119907A (zh) * | 2021-05-06 | 2023-11-24 | 雀巢产品有限公司 | 使用肌醇、赤藓糖醇或山梨糖醇中的至少一种来增强普拉梭菌生长的组合物和方法 |
WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0394655A (ja) * | 1989-09-06 | 1991-04-19 | Otsuka Pharmaceut Co Ltd | 栄養補給用組成物 |
JP4328473B2 (ja) * | 2001-04-09 | 2009-09-09 | 雪印乳業株式会社 | 肥満予防改善飲食品 |
FI20020078A (fi) * | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
JP2003334025A (ja) * | 2002-05-15 | 2003-11-25 | Toyo Shinyaku:Kk | 健康食品 |
DE60330781D1 (de) * | 2002-08-06 | 2010-02-11 | Danisco | Anwendung von lactobacillus zur herstellung von exopolysacchariden in nahrungsmittel und pharmazeutische zusammensetzungen |
GB0302872D0 (en) * | 2003-02-10 | 2003-03-12 | Univ Liverpool | Treatment of inflammatory bowel disease |
CA2684902A1 (en) * | 2007-05-23 | 2008-12-04 | Tate & Lyle Ingredients Americas, Inc. | Edible composition comprising a slowly digestible or digestion resistant oligosaccharide composition |
GB0903016D0 (en) * | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
US8816067B2 (en) * | 2009-05-07 | 2014-08-26 | Tate & Lyle Ingredients France SAS | Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans |
-
2012
- 2012-11-01 EP EP12845672.0A patent/EP2773357A4/en not_active Withdrawn
- 2012-11-01 IN IN4055CHN2014 patent/IN2014CN04055A/en unknown
- 2012-11-01 WO PCT/US2012/063008 patent/WO2013067146A1/en active Application Filing
- 2012-11-01 JP JP2014540070A patent/JP2014532710A/ja active Pending
- 2012-11-01 CA CA2854398A patent/CA2854398A1/en not_active Abandoned
- 2012-11-01 CN CN201280064861.5A patent/CN104159588A/zh active Pending
- 2012-11-01 BR BR112014010660A patent/BR112014010660A2/pt not_active IP Right Cessation
- 2012-11-01 MX MX2014005433A patent/MX2014005433A/es not_active Application Discontinuation
- 2012-11-01 AU AU2012332491A patent/AU2012332491A1/en not_active Abandoned
- 2012-11-01 US US14/355,963 patent/US20150209383A1/en not_active Abandoned
- 2012-11-01 KR KR1020147014663A patent/KR20140093252A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2854398A1 (en) | 2013-05-10 |
US20150209383A1 (en) | 2015-07-30 |
BR112014010660A2 (pt) | 2017-05-09 |
AU2012332491A1 (en) | 2014-05-29 |
WO2013067146A1 (en) | 2013-05-10 |
CN104159588A (zh) | 2014-11-19 |
EP2773357A1 (en) | 2014-09-10 |
EP2773357A4 (en) | 2015-08-26 |
JP2014532710A (ja) | 2014-12-08 |
MX2014005433A (es) | 2014-08-22 |
KR20140093252A (ko) | 2014-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04055A (ru) | ||
Li et al. | Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice | |
Xu et al. | Function of Akkermansia muciniphila in obesity: interactions with lipid metabolism, immune response and gut systems | |
Li et al. | Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota | |
Quezada et al. | Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics | |
Zou et al. | Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice | |
Shang et al. | Characterization of fecal fat composition and gut derived fecal microbiota in high-fat diet fed rats following intervention with chito-oligosaccharide and resistant starch complexes | |
Zhang et al. | Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha | |
Chen et al. | Bamboo-shaving polysaccharide protects against high-diet induced obesity and modulates the gut microbiota of mice | |
Liu et al. | Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice | |
Yuan et al. | Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice | |
Song et al. | Dietary anthocyanin-rich extract of açai protects from diet-induced obesity, liver steatosis, and insulin resistance with modulation of gut microbiota in mice | |
Singh et al. | Gut microbiome as a novel cardiovascular therapeutic target | |
JP2015523362A5 (ru) | ||
NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
WO2011097273A8 (en) | Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine | |
Zhou et al. | Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring | |
MX2012012777A (es) | Agentes de union del receptor nuclear. | |
JP2008113671A5 (ru) | ||
NZ602249A (en) | Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders | |
WO2010136900A3 (en) | Methods of using krill oil to treat risk factors for metabolic disorders and obesity | |
Wan et al. | The impact of dietary sn-2 palmitic triacylglycerols in combination with docosahexaenoic acid or arachidonic acid on lipid metabolism and host faecal microbiota composition in Sprague Dawley rats | |
Aoki et al. | Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice | |
Li et al. | Crude polysaccharide extracted from Moringa oleifera leaves prevents obesity in association with modulating gut microbiota in high-fat diet-fed mice | |
Zhao et al. | Selenium-enriched Bifidobacterium longum DD98 relieves metabolic alterations and liver injuries associated with obesity in high-fat diet-fed mice |